Patent offices

Joint Study by European Patent Office (EPO) and International Energy Agency (IEA) Shows Asia Ahead of U.S. in Battery Technology Innovation

Retrieved on: 
Tuesday, September 22, 2020
Intellectual property law, Government, Countries, European Patent Organisation, International Searching and Preliminary Examining Authorities, Patent offices, Patent law, Patent family, European Patent Office, Patent application, European Patent Convention, Term of patent

Looking at the longer term from 2000-18 shows a different ranking: the U.S. holds a share of 14.5% of all patent applications in batteries (No.

Key Points: 
  • Looking at the longer term from 2000-18 shows a different ranking: the U.S. holds a share of 14.5% of all patent applications in batteries (No.
  • Overall, more than 7,000 international patent families related to electricity storage were published in 2018, up from 1,000 in the year 2000.
  • International patent families: The patent analysis in this report is based on the concept of international patent families (IPFs).
  • With nearly 7,000 staff, the European Patent Office (EPO) is one of the largest public service institutions in Europe.

Enlivex Announces Allowance of New Chinese Patent Covering Allocetra Immunotherapy

Retrieved on: 
Wednesday, September 16, 2020
Patent offices, Cancer immunotherapy, National Intellectual Property Administration, Science and technology in China, State Council of the People's Republic of China, Immunotherapy, Patent

Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRATM, the companys immunotherapy product candidate.

Key Points: 
  • Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for a new patent application covering ALLOCETRATM, the companys immunotherapy product candidate.
  • Upon issuance, the new patent will provide added intellectual property protection, including methods, uses and pharmaceutical compositions.
  • The company expects that this new patent will be issued in China during the fourth quarter of 2020.
  • Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing.

Comscore Awarded New US Patent for Household Device Identification

Retrieved on: 
Wednesday, September 16, 2020
Intellectual property law, Patent offices, comScore, United States Patent and Trademark Office, Patent and Trademark Office, United States patent law

RESTON, Va., Sept. 16, 2020 /PRNewswire/ -- Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, is proud to announce that the US Patent and Trademark Office (USPTO) has granted its patent on "Device Identification System and Methods."

Key Points: 
  • RESTON, Va., Sept. 16, 2020 /PRNewswire/ -- Comscore (NASDAQ: SCOR), a trusted partner for planning, transacting, and evaluating media across platforms, is proud to announce that the US Patent and Trademark Office (USPTO) has granted its patent on "Device Identification System and Methods."
  • This patent, which was accepted by the USPTO on the very first round, covers Comscore's method of using household router meters to anonymously identify individuals within a household.
  • The invention will enable Comscore to draw even more precise, granular insights into consumer behavior for its best-in-class digital and cross-platform measurement.
  • Comscore's continued commitment to research and innovation is reflected by the numerous U.S. patents it has been granted over the last five years, including a recent patent for device co-location identification.

Mylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mL

Retrieved on: 
Tuesday, September 15, 2020
Countries, Government, Foreign relations, European Patent Organisation, Canonsburg, Pennsylvania, Mylan, MYL, Glatiramer acetate, European patent law, Teva Pharmaceuticals, Patent offices, European Patent Convention

HERTFORDSHIRE, England and PITTSBURGH, Sept. 15, 2020 /PRNewswire/ --Mylan N.V. (NASDAQ: MYL) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Company, Ltd.'s European Patent no.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, Sept. 15, 2020 /PRNewswire/ --Mylan N.V. (NASDAQ: MYL) today announced that the Technical Board of Appeal of the European Patent Office (EPO) has held that Yeda Research and Development Company, Ltd.'s European Patent no.
  • 2 949 335 related to Teva's Copaxone 40 mg/mL three times weekly product is invalid and revoked across Europe.
  • The EPO's positive ruling will allow Mylan to immediately return to the market and accelerate commercialization in other markets across Europe.
  • Mylan undertakes no obligation to update these statements for revisions or changes after the date of this release.

AgJunction Secures Patent for Three-Dimensional Terrain Mapping

Retrieved on: 
Tuesday, September 8, 2020
Intellectual property law, Intellectual property organizations, International Searching and Preliminary Examining Authorities, Patent offices, United States Patent and Trademark Office, United States trademark law, Intellectual property

SCOTTSDALE, Ariz., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AgJunction Inc. (TSX: AJX), ("AgJunction"), announced that it has been awarded another new patent from the U.S. Patent and Trademark Office titled Three-Dimensional Terrain Mapping.

Key Points: 
  • SCOTTSDALE, Ariz., Sept. 08, 2020 (GLOBE NEWSWIRE) -- AgJunction Inc. (TSX: AJX), ("AgJunction"), announced that it has been awarded another new patent from the U.S. Patent and Trademark Office titled Three-Dimensional Terrain Mapping.
  • The invention generates and utilizes three-dimensional terrain maps for vehicular control, including automatically or semi-automatically moving a vehicle along a desired path.
  • I am pleased to announce another addition to our extensive IP portfolio, said Luke McBeath, Sr. Director of Engineering at AgJunction.
  • The Three-Dimensional Terrain Mapping patent is another step towards expanding our farm automation and making life easier for farmers.

Clarivate Improves Trademark Search for the Benelux Office for Intellectual Property

Retrieved on: 
Tuesday, September 8, 2020
Intellectual property organizations, Intellectual property law, Benelux, Intangible assets, Benelux Office for Intellectual Property, Patent offices, Intellectual Property Office, Intellectual property, Trademark, IP

BOIP joins innovative IP offices around the world like the EU Intellectual Property Office, IP Australia and the Intellectual Property Office of Singaporewho have adopted image recognition (IR)1and new technologies to deliver innovative and more accessible services to users.

Key Points: 
  • BOIP joins innovative IP offices around the world like the EU Intellectual Property Office, IP Australia and the Intellectual Property Office of Singaporewho have adopted image recognition (IR)1and new technologies to deliver innovative and more accessible services to users.
  • Users can quickly determine whether a proposed image trademark is acceptable or if it infringes on an existing trademark.
  • This includes the European Union Intellectual Property Office (EUIPO), Georgia's Sakpatenti, IP Australia (IPA) and the IP Office of Singapore (IPOS).
  • The Benelux Office for Intellectual Property (BOIP) is theofficialbodyfor trademarks and designs registration in the Benelux.

Clarivate Improves Trademark Search for the Benelux Office for Intellectual Property

Retrieved on: 
Tuesday, September 8, 2020
Intellectual property organizations, Intellectual property law, Benelux, Intangible assets, Benelux Office for Intellectual Property, Patent offices, Intellectual Property Office, Intellectual property, Trademark, IP

BOIP joins innovative IP offices around the world like the EU Intellectual Property Office, IP Australia and the Intellectual Property Office of Singaporewho have adopted image recognition (IR)1and new technologies to deliver innovative and more accessible services to users.

Key Points: 
  • BOIP joins innovative IP offices around the world like the EU Intellectual Property Office, IP Australia and the Intellectual Property Office of Singaporewho have adopted image recognition (IR)1and new technologies to deliver innovative and more accessible services to users.
  • Users can quickly determine whether a proposed image trademark is acceptable or if it infringes on an existing trademark.
  • This includes the European Union Intellectual Property Office (EUIPO), Georgia's Sakpatenti, IP Australia (IPA) and the IP Office of Singapore (IPOS).
  • The Benelux Office for Intellectual Property (BOIP) is theofficialbodyfor trademarks and designs registration in the Benelux.

DGAP-News: Immune Regulation Limited: Immune Regulation Ltd receives notice of allowance for new U.S. patent for its novel protein with anti-inflammatory properties

Retrieved on: 
Tuesday, September 8, 2020
Intellectual property law, Intangible assets, Intellectual property organizations, International Searching and Preliminary Examining Authorities, Patent offices, Patent law, United States Patent and Trademark Office, Patent, Intellectual property, Immune Regulation, IRL201805

Immune Regulation Limited: Immune Regulation Ltd receives notice of allowance for new U.S. patent for its novel protein with anti-inflammatory properties

Key Points: 
  • Immune Regulation Limited: Immune Regulation Ltd receives notice of allowance for new U.S. patent for its novel protein with anti-inflammatory properties
    The issuer is solely responsible for the content of this announcement.
  • Immune Regulation Ltd receives notice of allowance for new U.S. patent for its novel protein with anti-inflammatory properties
    (London UK, 08 September 2020) Immune Regulation Ltd, a US and UK based clinical stage biotechnology company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering IRL201805 ('1805).
  • The new patent provides Immune Regulation with additional intellectual property protection covering the composition of matter of '1805.
  • "This new '1805 patent significantly strengthens Immune Regulation's intellectual property portfolio," said Jonathan Rigby, Group CEO of Immune Regulation.

UVision360 Announces Publication of Novel Biopsy Patent for the LUMINELLE® DTx System

Retrieved on: 
Tuesday, September 1, 2020
Intellectual property law, Patent offices, Biopsy, Interventional radiology, United States Patent and Trademark Office, Patent and Trademark Office

The United States Patent and Trademark Office (USPTO) has issued patent 10,758,214 titled "BIOPSY DEVICE AND METHOD."

Key Points: 
  • The United States Patent and Trademark Office (USPTO) has issued patent 10,758,214 titled "BIOPSY DEVICE AND METHOD."
  • The allowed claims cover the novel biopsy sleeve, biopsy system which allows for visualization, and a method of collecting a biopsy sample.
  • "With procedures moving out of the hospital and into the gynecologist's office, this patent further protects the uniqueness of the LUMINELLE System," said Allison London Brown, CEO of UVision360.
  • The company has created the LUMINELLE DTx System, a simplified, compact and modular endoscopic system employing the latest in high-tech optics and interchangeable accessories to meet the needs of physicians and patients.

Clearside Biomedical Expands Patent Portfolio in the U.S. and Europe

Retrieved on: 
Wednesday, August 26, 2020
Intellectual property law, Patent offices, United States Patent and Trademark Office, United States trademark law, Patent, United States patent law

The United States Patent and Trademark Office (USPTO) recently granted patent number10,722,396to Clearside.

Key Points: 
  • The United States Patent and Trademark Office (USPTO) recently granted patent number10,722,396to Clearside.
  • This patent covers Clearsides SCS Microinjector for the suprachoroidal administration of axitinib (CLS-AX) and expires in 2034.
  • Patent number 2,563,429 expires in 2031 and covers a device for the suprachoroidal administration of any therapeutic agent.
  • We are committed to broadening our global patent estate as we continue to expand our internal pipeline and increase patient access to innovative therapies.